

TML: CS: 2017-18:

12th December, 2017

The General Manager
Dept. of Corporate Services
Bombay Stock Exchange Ltd.
Rotunda Building, 1st Floor,
Mumbai Samachar Marg,
Mumbai- 400 001.

The Vice President
Listing Department,
National Stock Exchange of India Ltd.
"Exchange Plaza", Bandra – Kurla
Complex,
Bandra – East,
Mumbai- 400 051.

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

Meeting Commencement time : 11:45 A.M
Meeting Conclusion Time : 02:00 P.M

The Board of Directors at its meeting held today, approved the following matters:

1. Approved the Unaudited Consolidated and Standalone Financial Results of the Company for the Quarter and half year ended on 30th September, 2017.
2. Allotment of 1391 Equity shares to eligible employees' pursuant exercise of ESOPs under Themis ESOS Scheme 2012.

A copy of Unaudited Standalone Financial Results of the Company for the Quarter/ half year ended on 30th September, 2017 together with Limited Review Report is enclosed for your perusal.

This may be taken as compliance under the Listing Regulations.

Kindly take the same on record and acknowledge receipt.

Thanking you,
Yours faithfully,

For **THEMIS MEDICARE LIMITED**



SANGAMESHWAR IYER
Company Secretary & Compliance Officer

Themis Medicare Limited

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai - 400 104 India
Tel. : 91-22-6760 7080 • Fax : 91-22-6760 7070 / 2874 6621

Regd. Office : Plot No. 69-A, G.I.D.C. Industrial Estate, Vapi - 396 195, Gujarat

CIN No.: L24110GJ1969PLC001590 • Tel / Fax No.: Regd. Off. : 0260 2431447 / 2430219

• E-mail : themis@themismedicare.com • Website : www.themismedicare.com



Raju P. Sardar
B.Com., F.C.A.

R. P. Sardar & Co.
Chartered Accountants

102, Beuna Vista, Next to ICICI Bank, Holy Cross Road,
I. C. Colony, Borivali (West), Mumbai - 400 103.
Tel.: 2893 3556 / 6563 3556 • Mobile : 98212 16687
E-mail : rpsardar@gmail.com

To
Board of Directors of
THEMIS MEDICARE LIMITED
Mumbai

Limited Review of the Unaudited Standalone Financial Results for the Quarter and half year ended on September 30, 2017.

We have reviewed the accompanying statement of Unaudited Standalone Financial Results of Themis Medicare Limited (the 'Company') for the quarter and half year ended September 30, 2017 (the 'Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

The preparation of the Statement is in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (India Accounting Standards) Rules, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The comparative financial results of the company for the immediately preceding quarter ended June 30, 2017 and corresponding quarter ended September 30, 2016 were reviewed by the predecessor auditor who issued a limited review report on those quarterly financial results on September 04, 2017 and November 08, 2016 respectively. The financial statements for the year ended March 31, 2017 were audited by the predecessor auditor who expressed an unmodified opinion on those financial statements on May 10, 2017.





Raju P. Sardar
B.Com., F.C.A.

R. P. Sardar & Co.
Chartered Accountants

102, Beuna Vista, Next to ICICI Bank, Holy Cross Road,
I. C. Colony, Borivali (West), Mumbai - 400 103.
Tel.: 2893 3556 / 6563 3556 • Mobile : 98212 16687
E-mail : rpsardar@gmail.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standard ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We have not reviewed the Financial Results and other financial information for the corresponding quarter and half year ended September 30, 2016, which has been presented solely based on the information, compiled by the Management and has been approved by the Board of Directors of the Company.

For **R. P. Sardar & Co.**
Chartered Accountants
Registration No. 109273W



Raju P Sardar
Proprietor
Membership No. 037845

Place: Mumbai
Date: 12.12.2017

THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

Statement of Unaudited Financial Results for the quarter and half year ended 30th September 2017.

(Amount in INR Lakhs)

	Particulars	STANDALONE				
		3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Year to date figures for the current period ended	Year to date figures for the previous period ended
		30/09/2017	30/06/2017	30/09/2016	30/09/2017	30/09/2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	Revenue from Operations	6,206.35	4,744.00	5,941.69	10,950.35	11,726.84
2	Other Income	166.14	27.43	58.71	193.57	244.54
3	Total Income (1 + 2)	6,372.49	4,771.43	6,000.40	11,143.92	11,971.38
4	Expenses :					
	(a) Cost of materials consumed	1,537.90	1,172.29	1,483.61	2,710.20	2,814.38
	(b) Purchases of stock-in-trade	561.40	666.65	589.17	1,228.06	1,019.23
	(c) Changes in inventories of finished goods,work-in-progress and stock-in-trade	583.53	(298.09)	(255.23)	285.44	7.53
	(d) Excise Duty	0.00	220.34	298.61	220.34	404.17
	(e) Employee benefits expense	1,098.54	1,065.34	986.90	2,163.88	2,005.29
	(f) Finance Costs	344.45	299.70	297.30	644.15	609.42
	(g) Depreciation and amortisation expense	178.06	170.64	180.12	348.71	351.89
	(h) Other expenses	1,476.41	1,857.10	2,484.32	3,333.51	4,321.47
	Total expenses	5,780.29	5,153.97	6,064.80	10,934.29	11,533.38
5	Profit / (Loss) before exceptional items and tax (3 - 4)	592.20	(382.54)	(64.40)	209.63	438.00
6	Exceptional Items	-	-	-	-	-
7	Profit / (Loss) before tax (5 - 6)	592.20	(382.54)	(64.40)	209.63	438.00
8	Tax expense :					
	(a) Current Tax	-	-	-	-	-
	(b) Deferred Tax	(36.75)	(13.55)	(288.32)	(50.30)	(301.88)
9	Profit / (Loss) for the period (7 - 8)	628.95	(368.99)	223.92	259.93	739.88
10	Other Comprehensive Income :					
	(a i) Items that will not be reclassified to Profit & Loss	0.68	0.65	0.17	1.33	0.34
	(a ii) Income Tax relating to Items that will not be reclassified to Profit & Loss	(0.40)	(0.06)	(0.06)	(0.46)	(0.12)
	(b) Items that will be reclassified to Profit & Loss	-	-	-	-	-
11	Total Comprehensive Income for the period (9 + 10)	629.23	(368.40)	224.03	260.80	740.10
12	Paid up Equity Share Capital (Face Value of Rs.10/- per Equity Share)	904.63	904.44	903.03	904.63	903.03
13	Earnings per share :					
	(a) Basic	6.95	(4.08)	2.48	2.87	8.19
	(b) Diluted	6.78	(4.08)	2.41	2.80	7.98



NOTES:

- 1) The Company has only one segment namely pharmaceuticals and hence, no separate segmentwise disclosure has been made.
- 2) During the quarter under review, paid up share capital of the Company increased from Rs. 904.44 lakhs to Rs. 904.63 lakhs in view of allotment of 1940 equity shares on exercise of ESOP by some of the eligible employees.
- 3) In terms of SEBI (ICDR) Regulations, 2009 the Board at its meeting held on 17th June, 2016 allotted 500000 Equity Shares on Preferential Basis to Non Promoters and 125000 Convertible Warrants to some of the Promoters of the Company. The proceeds received amounted to Rs. 2656.25 lakhs. In terms of the Regulation 32 of the SEBI (LODR) Regulations, 2015 we state that there was no deviation of proceeds utilised for the period ended September, 2017 from the purposes mentioned in Private Placement Offer Letter.
- 4) The above results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12.12.2017.
- 5) The Company has adopted Indian Accounting Standards ("Ind AS") from April 1, 2017 and accordingly these financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable to the Company. The date of transition to Ind AS is April 1, 2016. The impact of transition has been accounted for in the opening results and the comparative period results have been restated accordingly. The opening Balance Sheet as at April 1, 2016 and the results for the subsequent period would get published along with the annual financial statements for the year ending March 31, 2018
- 6) The Ind AS compliant financial results, pertaining to the quarter and half year ended September 30, 2016 have not been subjected to limited review or audit. However, the management has exercised necessary due diligence to ensure that such financial results provide true and fair view of its affairs.
- 7) The Statement does not include Ind AS compliant Statement of Assets and Liabilities for the previous period as the same are not mandatory as per SEBI's Circular dated 5th July, 2016
- 8) Revenue from operations has been presented in accordance with Ind AS 18. For the previous periods, the revenue has been shown as gross of excise duty (as applicable) and for the current period as net of Goods and Service Tax (GST) (as applicable). Hence, Revenue from operations for the previous periods are not comparable with the current period.
- 9) Reconciliation of Net Profit as previously reported on account of transition from the previous GAAP to Ind AS for the quarter ended 30th September, 2016:

Particulars	(Amount in INR Lakhs)	
	For the Quarter ended September 30, 2016	For the Half year ended September 30, 2016
Net Profit as per previous GAAP	707.38	1,257.18
Fair Valuation of Financial Instruments	13.55	14.16
Fair Valuation of Financial guarantees	0.63	1.25
Interest expenses accounted using effective interest rate	(21.07)	(51.81)
Effect of Expected credit loss on financial assets	(742.43)	(742.43)
Depreciation on property, plant and equipment measured at fair value as deemed cost on date of transition	(8.78)	(13.02)
Actuarial (gain)/ Loss on employee defined benefit fund recognised in Other Comprehensive Income	(0.17)	(0.34)
Effect of deferred tax on adjustments	274.81	274.89
Net Profit for the period as per Ind AS	223.92	739.88
Other Comprehensive Income	0.11	0.22
Total Comprehensive Income under Ind AS	224.03	740.10



THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

(Amount in INR Lakhs)

BALANCE SHEET AS AT SEPTEMBER 30, 2017

(STANDALONE)

Particulars	As at 30th September, 2017
ASSETS	
Non-Current Assets	
(a) Property, Plant and Equipment	12,123.22
(b) Capital Work-in-Progress	719.74
(c) Intangible Assets	197.16
(d) Financial Assets	
(i) Investments	1,095.99
(ii) Other Financial Assets	25.52
(e) Deferred Tax Asset (Net)	449.08
(f) Other Non-Current Assets	642.95
	15,253.66
Current assets	
(a) Inventories	4,508.78
(b) Financial Assets	
(i) Investments	(0.00)
(ii) Trade Receivables	6,676.66
(iii) Cash and Cash Equivalents	585.17
(iv) Bank Balances Other than (iii) above	217.35
(v) Other Financial Assets	363.56
(c) Other Current Assets	1,618.70
	13,970.22
TOTAL	29,223.88
EQUITY AND LIABILITIES	
Equity	
(a) Equity Share capital	904.63
(b) Other Equity	13,473.61
	14,378.24
Liabilities	
Non Current Liabilities	
(a) Financial Liabilities	
(i) Borrowings	1,682.48
	1,682.48
Current Liabilities	
(a) Financial Liabilities	
(i) Borrowings	5,329.92
(ii) Trade Payables	
Micro, Small and Medium Enterprises	91.85
Others	3,372.05
(iii) Other Financial Liabilities	3,459.21
(b) Other Current Liabilities	578.04
(c) Provisions	103.00
(d) Current Tax Liabilities (Net)	229.09
	13,163.16
TOTAL	29,223.88

For R. P. Sardar & Co.
Chartered Accountants



Raju P. Sardar
Proprietor



By Order of the Board
For THEMIS MEDICARE LTD



Dr. SACHIN PATEL
(Managing Director & CEO)



Place : Mumbai

Date : 12 / 12 / 2017



Raju P. Sardar
B.Com., F.C.A.

R. P. Sardar & Co.
Chartered Accountants

102, Beuna Vista, Next to ICICI Bank, Holy Cross Road,
I. C. Colony, Borivali (West), Mumbai - 400 103.
Tel.: 2893 3556 / 6563 3556 • Mobile : 98212 16687
E-mail : rpsardar@gmail.com

To
Board of Directors of
THEMIS MEDICARE LIMITED
Mumbai

Limited Review of the Unaudited Consolidated Financial Results for the Quarter and half year ended on September 30, 2017.

We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of Themis Medicare Limited (the 'Company') for the quarter and half year ended September 30, 2017 (the 'Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.

The preparation of the Statement is in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (India Accounting Standards) Rules, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The comparative financial results of the company for the immediately preceding quarter ended June 30, 2017 and corresponding quarter ended September 30, 2016 were reviewed by the predecessor auditor who issued a limited review report on those quarterly financial results on September 04, 2017 and November 08, 2016 respectively. The financial statements for the year ended March 31, 2017 were audited by the predecessor auditor who expressed an unmodified opinion on those financial statements on May 10, 2017.





Raju P. Sardar
B.Com., F.C.A.

R. P. Sardar & Co.
Chartered Accountants

102, Beuna Vista, Next to ICICI Bank, Holy Cross Road,
I. C. Colony, Borivali (West), Mumbai - 400 103.
Tel.: 2893 3556 / 6563 3556 • Mobile : 98212 16687
E-mail : rpsardar@gmail.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standard ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We have not reviewed the Financial Results and other financial information for the corresponding quarter and half year ended September 30, 2016, which has been presented solely based on the information, compiled by the Management and has been approved by the Board of Directors of the Company.

For **R. P. Sardar & Co.**
Chartered Accountants
Registration No. 109273W



Raju P Sardar
Proprietor
Membership No. 037845

Place: Mumbai
Date: 12.12.2017

THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

Statement of Unaudited Financial Results for the quarter and half year ended 30th September 2017.

(Amount in INR Lakhs)

	Particulars	CONSOLIDATED				
		3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Year to date figures for the current period ended	Year to date figures for the previous period ended
		30/09/2017	30/06/2017	30/09/2016	30/09/2017	30/09/2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	Revenue from Operations	6,206.35	4,744.00	5,941.69	10,950.35	11,726.84
2	Other Income	166.14	27.43	58.71	193.57	244.54
3	Total Income (1 + 2)	6,372.49	4,771.43	6,000.40	11,143.92	11,971.38
4	Expenses :					
	(a) Cost of materials consumed	1,537.90	1,172.29	1,483.61	2,710.20	2,814.38
	(b) Purchases of stock-in-trade	561.40	666.65	589.17	1,228.06	1,019.23
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	583.53	(298.09)	(255.23)	285.44	7.53
	(d) Excise Duty	0.00	220.34	298.61	220.34	404.17
	(e) Employee benefits expense	1,098.54	1,065.34	986.90	2,163.88	2,005.29
	(f) Finance Costs	344.45	299.70	297.30	644.15	609.42
	(g) Depreciation and amortisation expense	178.06	170.64	180.12	348.71	351.89
	(h) Other expenses	1,476.41	1,857.10	2,484.32	3,333.51	4,321.47
	Total expenses	5,780.29	5,153.97	6,064.80	10,934.29	11,533.38
5	Profit / (Loss) before exceptional items, share of Profit / (Loss) of associates and tax (3 - 4)	592.20	(382.54)	(64.40)	209.63	438.00
6	Exceptional Items	-	-	-	-	-
7	Profit / (Loss) before share of Profit / (Loss) of associates and tax (5 - 6)	592.20	(382.54)	(64.40)	209.63	438.00
8	Add: Share of Profit / (Loss) of associates for the period	72.82	68.35	(9.75)	141.17	175.80
9	Profit / (Loss) before tax (7 + 8)	665.02	(314.19)	(74.15)	350.80	613.80
10	Tax expense :					
	(a) Current Tax	-	-	-	-	-
	(b) Deferred Tax	(36.75)	(13.55)	(288.32)	(50.30)	(301.88)
11	Profit / (Loss) for the period (9 - 10)	701.77	(300.64)	214.17	401.10	915.68
12	Other Comprehensive Income :					
	(a i) Items that will not be reclassified to Profit & Loss	0.68	0.65	0.17	1.33	0.34
	(a ii) Income Tax relating to Items that will not be reclassified to Profit & Loss	(0.40)	(0.06)	(0.06)	(0.46)	(0.12)
	(b) Items that will be reclassified to Profit & Loss	-	-	-	-	-
13	Total Comprehensive Income for the period (11 + 12)	702.05	(300.05)	214.28	401.97	915.90
14	Paid up Equity Share Capital (Face Value of Rs.10/- per Equity Share)	904.63	904.44	903.03	904.63	903.03
15	Earnings per share :					
	(a) Basic	7.76	(3.32)	2.37	4.43	10.14
	(b) Diluted	7.57	(3.32)	2.31	4.32	9.87



NOTES :

- 1) The Company has only one segment namely pharmaceuticals and hence, no separate segmentwise disclosure has been made.
- 2) During the quarter under review, paid up share capital of the Company increased from Rs. 904.44 lakhs to Rs. 904.63 lakhs in view of allotment of 1940 equity shares on exercise of ESOP by some of the eligible employees.
- 3) In terms of SEBI (ICDR) Regulations, 2009 the Board at its meeting held on 17th June, 2016 allotted 500000 Equity Shares on Preferential Basis to Non Promoters and 125000 Convertible Warrants to some of the Promoters of the Company. The proceeds received amounted to Rs. 2656.25 lakhs. In terms of the Regulation 32 of the SEBI (LODR) Regulations, 2015 we state that there was no deviation of proceeds utilised for the period ended September, 2017 from the purposes mentioned in Private Placement Offer Letter.
- 4) The above results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 12.12.2017.
- 5) The Company has adopted Indian Accounting Standards ("Ind AS") from April 1, 2017 and accordingly these financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable to the Company. The date of transition to Ind AS is April 1, 2016. The impact of transition has been accounted for in the opening results and the comparative period results have been restated accordingly. The opening Balance Sheet as at April 1, 2016 and the results for the subsequent period would get published along with the annual financial statements for the year ending March 31, 2018
- 6) The Ind AS compliant financial results, pertaining to the quarter and half year ended September 30, 2016 have not been subjected to limited review or audit. However, the management has exercised necessary due diligence to ensure that such financial results provide true and fair view of its affairs.
- 7) The Statement does not include Ind AS compliant Statement of Assets and Liabilities for the previous period as the same are not mandatory as per SEBI's Circular dated 5th July, 2016
- 8) Revenue from operations has been presented in accordance with Ind AS 18. For the previous periods, the revenue has been shown as gross of excise duty (as applicable) and for the current period as net of Goods and Service Tax (GST) (as applicable). Hence, Revenue from operations for the previous periods are not comparable with the current period.
- 9) Reconciliation of Net Profit as previously reported on account of transition from the previous GAAP to Ind AS for the quarter ended 30th September, 2016:

(Amount in INR Lakhs)

Particulars	For the Quarter ended September 30, 2016	For the Half year ended September 30, 2016
Net Profit as per previous GAAP	698.49	1,432.72
Fair Valuation of Financial Instruments	13.23	18.66
Fair Valuation of Financial guarantees	0.63	1.25
Interest expenses accounted using effective interest rate	(21.07)	(51.81)
Prior period adjustment	0.02	(0.02)
Effect of Expected credit loss on financial assets	(742.43)	(742.43)
Depreciation on property, plant and equipment measured at fair value as deemed cost on date of transition	(8.78)	(13.02)
Actuarial (gain)/ Loss on employee defined benefit fund recognised in Other Comprehensive Income	(0.74)	0.07
Other Adjustment	-	(4.20)
Effect of deferred tax on adjustments	274.81	274.46
Net Profit for the period as per Ind AS	214.17	915.68
Other Comprehensive Income	0.11	0.22
Total Comprehensive Income under Ind AS	214.28	915.90



THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

(Amount in INR Lakhs)

BALANCE SHEET AS AT SEPTEMBER 30, 2017

(CONSOLIDATED)

Particulars	As at 30th September, 2017
ASSETS	
Non-Current Assets	
(a) Property, Plant and Equipment	12,123.22
(b) Capital Work-in-Progress	719.74
(c) Intangible Assets	197.16
(d) Financial Assets	
(i) Investments	1,234.27
(ii) Other Financial Assets	25.52
(e) Deferred Tax Asset (Net)	449.09
(f) Other Non-Current Assets	642.95
	15,391.95
Current assets	
(a) Inventories	4,508.78
(b) Financial Assets	
(i) Investments	(0.00)
(ii) Trade Receivables	6,676.66
(iii) Cash and Cash Equivalents	594.35
(iv) Bank Balances Other than (iii) above	217.35
(v) Other Financial Assets	363.56
(c) Other Current Assets	1,612.40
	13,973.10
TOTAL	29,365.05
EQUITY AND LIABILITIES	
Equity	
(a) Equity Share capital	904.63
(b) Other Equity	13,614.78
	14,519.41
Liabilities	
Non Current Liabilities	
(a) Financial Liabilities	
(i) Borrowings	1,682.48
	1,682.48
Current Liabilities	
(a) Financial Liabilities	
(i) Borrowings	5,329.92
(ii) Trade Payables	
Micro, Small and Medium Enterprises	91.85
Others	3,372.05
(iii) Other Financial Liabilities	3,459.21
(b) Other Current Liabilities	578.04
(c) Provisions	103.00
(d) Current Tax Liabilities (Net)	229.09
	13,163.16
TOTAL	29,365.05

For R. P. Sardar & Co.
Chartered Accountants




Raju P. Sardar
Proprietor

By Order of the Board
For THEMIS MEDICARE LTD




Dr. SACHIN PATEL
(Managing Director & CEO)

Place : Mumbai

Date : 12 / 12 / 2017